Preclinical models demonstrate 60–80% tumor growth inhibition in KRAS-mutated NSCLC with minimal systemic toxicity, underscoring the therapeutic window created by tumor-selective copper accumulation [126]. The gene discussed is KRAS; the disease is neoplasm.